Diagnocure CUR Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Diagnocure CUR

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert Dirks who wrote (97)	11/21/2000 2:00:30 PM
From: Mr. L. Neufeldt	Read Replies (1) of 132

(If anyone is interested in viewing the Desjardin report drop me a private message and your silicon email address and I'll forward it. I have it in English or French.) Well Robert, here we sit. I hope you got out of VVVV before it dropped. I read a recent report indicating that bio. companies have outperformed the market 100% of the time during a recessionary period. Diagnocure has been given a buy this month from Desjardin. 12 month target of $5.50/sh. I've noticed that most of the purchases of CUR have been through the Desjardin brokerage house. Looking at the charts it seems that CUR has finally bottomed out. Money is flowing in to keep it at a minimum of around $2.00/sh. CUR's current plan is to put the uPM3 out to other companies for joint clinical trials. Negotiating should take a minimum of 6 months. Around the same time CUR should be negotiating with a CRO. This time next year we should be advancing towards production in our GMP facility.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next